Zeo ScientifiX Files 8-K Reporting Other Events

TL;DR

Zeo ScientifiX filed an 8-K, but no juicy details yet.

AI Summary

Zeo ScientifiX, Inc. filed an 8-K on September 30, 2024, reporting "Other Events." The company, formerly known as Organicell Regenerative Medicine, Inc., is incorporated in Nevada and operates in the Biological Products sector. The filing does not disclose specific financial transactions or material events beyond the standard reporting requirement.

Why It Matters

This 8-K filing indicates Zeo ScientifiX, Inc. has made a regulatory submission, but it does not provide details on any significant business developments or financial changes.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for 'Other Events' and does not contain specific material information that would immediately impact the company's risk profile.

Key Players & Entities

• Zeo ScientifiX, Inc. (company) — Registrant
• Organicell Regenerative Medicine, Inc. (company) — Former company name
• September 30, 2024 (date) — Date of report
• Nevada (jurisdiction) — State of incorporation
• 3321 College Avenue, Suite 246 Davie, Florida 33314 (address) — Principal executive office address

FAQ

Key Financial Figures

• $175 billion — e space is expected to grow to a nearly $175 billion market by 2032, with a projected growth

Filing Documents

• zeoscientifix_8k.htm (8-K) — 38KB
• 0001829126-24-006533.txt ( ) — 204KB
• ocel-20240930.xsd (EX-101.SCH) — 3KB
• ocel-20240930_lab.xml (EX-101.LAB) — 33KB
• ocel-20240930_pre.xml (EX-101.PRE) — 22KB
• zeoscientifix_8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements Certain statements contained in this Report, including those regarding the impact of the impact of the partnership with Physicians Group, should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward- looking statements are often identified by the use of forward-looking terminology such as "will," "believes," "expects," "potential," or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. No assurances can be given that the Company will be successful in its research initiatives. In addition, no assurances can be given that our research initiatives will increase the price of our common stock to a level that is attractive to brokerage houses and institutional investors. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission (the " SEC ") and availa

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 30, 2024 ZEO SCIENTIFIX, INC. By: /s/ Ian T. Bothwell Ian T. Bothwell, Interim Chief Executive Officer and Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR